利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

5 条记录 (耗时 0.015 秒)

    Process for the preparation of solid pharmaceutical products
    2.
    发明授权
    Process for the preparation of solid pharmaceutical products 失效
    固体药物制剂的制备方法

    公开(公告)号：US4632843A

    公开(公告)日：1986-12-30

    申请号：US581714

    申请日：1984-02-21

    申请人： Claus H. Pich ,  Thomas Moest

    发明人： Claus H. Pich ,  Thomas Moest

    IPC分类号： C07C67/055 ,  A61K9/16 ,  A61K9/54 ,  A61K31/26 ,  A61K33/06 ,  A61K33/14 ,  C01D3/22 ,  C01F5/40 ,  C01G49/14 ,  C07C51/00 ,  C07C51/43 ,  C07C67/00 ,  C30B7/08 ,  C30B29/60 ,  A61K9/48

    CPC分类号： A61K9/1688 ,  C30B7/00 ,  Y10S514/951 ,  Y10S514/963 ,  Y10S514/965

    摘要： A process for the preparation of solid pharmaceutical products, wherein, in a first step, spherical single crystals of a pharmaceutical active compound or assistant are prepared by agitating a saturated aqueous, organic or organic-aqueous solution in high speed stirred crystallizers or draft-tube crystallizers at 50-500 revolutions per minute and seeding the solution with finely ground seed crystals of particle size less than 100 .mu.m, while ensuring that at the time of addition of the seed crystals and during the growth thereof the solution is at all times only minimally supersaturated, this being achieved by slow cooling at a rate of not more than 50 K/h or corresponding slow evaporation of the solution, and in a second step the resulting spherical single crystals with diameters of 0.1-3 mm, preferably 0.5-2 mm, are separated from the solution, dried at 40.degree.-200.degree. C., compounded, where appropriate, with suitable pharmaceutical assistants or, if the single crystals serve as assistants, with suitable pharmaceutical active compounds, and then converted to solid pharmaceutical products by coating, tableting or filling into hard gelatin capsules.

    摘要翻译： 一种制备固体药物产品的方法，其中在第一步中，通过在高速搅拌结晶器或引流管中搅拌饱和水溶液，有机或有机水溶液来制备药物活性化合物或助剂的球形单晶 结晶器以50-500转/分钟的速度接种，并用晶粒尺寸小于100微米的精细研磨晶种接种溶液，同时确保在加入晶种时，在其生长过程中溶液始终处于 最低限度过饱和，这是通过以不超过50K / h的速度缓慢冷却或相应的溶液缓慢蒸发来实现的，而在第二步中，得到的直径为0.1-3mm，优选为0.5-2的球形单晶 mm，与溶液分离，在40℃-200℃下干燥，在合适的情况下，用合适的药物助剂混合，或者如果单晶作为助剂 与合适的药物活性化合物混合，然后通过涂布，压片或填充到硬明胶胶囊中转化为固体药物产品。

    Stringently sodium-restricted dietetic salt and its preparation
    3.
    发明授权
    Stringently sodium-restricted dietetic salt and its preparation 失效
    严格限钠饮食及其制备

    公开(公告)号：US4340614A

    公开(公告)日：1982-07-20

    申请号：US267870

    申请日：1981-05-28

    申请人： Claus H. Pich ,  Thomas Moest

    发明人： Claus H. Pich ,  Thomas Moest

    IPC分类号： A23L27/23 ,  A23L27/40 ,  A23L1/237

    CPC分类号： A23L27/45 ,  A23L27/235

    摘要： A stringently sodium-restricted dietetic salt consisting of a mixture of from 60 to 85% by weight of potassium chloride, from 10 to 30% by weight of potassium adipate, from 2 to 5% by weight of potassium tartrate, from 0.5 to 2% by weight of potassium glutamate, from 0.5 to 2% by weight of adipic acid and a total of from 0.004 to 0.06% by weight of potassium inosate and/or potassium guanylate, and the preparation of the salt in a fluidized bed apparatus.

    摘要翻译： 严格的钠限制饮食盐，其由60至85重量％的氯化钾，10至30重量％的己二酸钾，2至5重量％的酒石酸钾，0.5至2重量％ 的谷氨酸钾，0.5至2重量％的己二酸和总计0.004至0.06重量％的氢氧化钾和/或鸟苷酸钾，以及在流化床装置中制备该盐。

    Manufacture of pellets of xanthine derivatives
    4.
    发明授权
    Manufacture of pellets of xanthine derivatives 失效
    XANTHINE衍生物颗粒的制备

    公开(公告)号：US5160469A

    公开(公告)日：1992-11-03

    申请号：US578442

    申请日：1990-09-07

    申请人： Thomas Moest ,  Claus H. Pich

    发明人： Thomas Moest ,  Claus H. Pich

    IPC分类号： A61K9/16 ,  A61K9/20 ,  A61K9/32 ,  A61K9/52 ,  A61K31/52

    CPC分类号： A61K9/1688 ,  A61K31/52

    摘要： A process for the manufacture of pellets which are composed of xanthine derivatives and are predominantly spherical, have a particle size in the range of 0.3 to 4 mm and have a bulk density above 0.5 g/cm.sup.3 by reacting the appropriate xanthine derivative with water or a water/alcohol mixture, entails anhydrous powdered xanthine derivative with an average particle size of from 20 to 200 .mu.m being suspended by stirring at from 40.degree. to 70.degree. C. in a nonsolvent which is immiscible with water and has a boiling point in the range from 60.degree. to 160.degree. C., then adding from 10 to 40% by weight, based on the anhydrous xanthine derivative, of water or a water/alcohol mixture and subsequently allowing to cool to room temperature at from 5.degree. to 20.degree. C. per hour, it being possible to reduce the stirring speed after agglomeration to about 1/3 to 2/3 of the original, and the pellets being separated from the liquid and dried, the pellets being used, possibly with a delayed release coating, as active compound in a drug.

    摘要翻译： 制造由黄嘌呤衍生物构成的并且主要为球形的颗粒的方法具有0.3-4mm的粒径，并且通过使适当的黄嘌呤衍生物与水或 水/醇混合物，使平均粒度为20〜200μm的无水粉末黄嘌呤衍生物在40℃至70℃下搅拌悬浮，在与水不混溶的非溶剂中，并且沸点在 范围为60〜160℃，然后以无水黄嘌呤衍生物为基础，以无水黄嘌呤衍生物为10〜40重量％的水或水/醇混合物，然后在5〜20℃下冷却至室温。 每小时可以将凝聚后的搅拌速度降低到原料的约1/3至2/3，并将颗粒与液体分离并干燥，使用颗粒，可能具有延迟释放涂层 ，as 药物中的活性化合物。